Related Experiment Videos
New therapies for advanced glycation end product nephrotoxicity: current challenges
1Joslin Diabetes Center and Harvard Medical School, Boston, MA, USA. mark.williams@joslin.harvard.edu
Background:
The role of advanced glycation end products (AGEs) in diabetic nephropathy has been developed during several years of research and increasingly complex AGE biochemistry. However, the structural diversity of AGE chemistry has created new challenges in the search for AGE-based inhibition therapies.
Results:
The challenges include the need to standardize measurements of serum and tissue AGE levels, identifying nephrotoxic AGE compounds, understanding the cell biological state of AGEs in the diabetic kidney, determining the mechanism of action of selective inhibition of the glycation cascade, and forming complementary therapies.
Conclusion:
Current challenges in the development of new therapies for AGE nephrotoxicity are reviewed.